AMF Tjanstepension AB Has $76.70 Million Stake in Stryker Corporation $SYK

Key Points

• AMF Tjanstepension AB increased its stake in Stryker Corporation by 319.9% in the second quarter, owning approximately 0.05% of the company worth $76.7 million after acquiring an additional 147,663 shares.
• Insider transactions revealed that Director Ronda E. Stryker sold 200,000 shares for about $75.29 million, resulting in a 5.84% decrease in her ownership.
• Stryker reported a 12.25% net margin and 11.1% year-over-year revenue growth, with a beat on EPS estimates at $3.13, exceeding expectations of $3.07.

AMF Tjanstepension AB boosted its stake in Stryker Corporation (NYSE:SYK - Free Report) by 319.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 193,817 shares of the medical technology company's stock after buying an additional 147,663 shares during the quarter. AMF Tjanstepension AB owned approximately 0.05% of Stryker worth $76,697,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of SYK. LGT Fund Management Co Ltd. boosted its stake in Stryker by 23.5% in the second quarter. LGT Fund Management Co Ltd. now owns 4,901 shares of the medical technology company's stock worth $1,939,000 after purchasing an additional 934 shares in the last quarter. Tilia Fiduciary Partners Inc. boosted its stake in Stryker by 1.1% in the second quarter. Tilia Fiduciary Partners Inc. now owns 7,266 shares of the medical technology company's stock worth $2,875,000 after purchasing an additional 78 shares in the last quarter. Cape ANN Savings Bank boosted its stake in Stryker by 6.7% in the second quarter. Cape ANN Savings Bank now owns 2,611 shares of the medical technology company's stock worth $1,033,000 after purchasing an additional 165 shares in the last quarter. Consolidated Investment Group LLC boosted its stake in Stryker by 7.1% in the second quarter. Consolidated Investment Group LLC now owns 10,510 shares of the medical technology company's stock worth $4,158,000 after purchasing an additional 700 shares in the last quarter. Finally, Ascent Group LLC boosted its stake in Stryker by 1.3% in the second quarter. Ascent Group LLC now owns 5,809 shares of the medical technology company's stock worth $2,298,000 after purchasing an additional 75 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Viju Menon sold 500 shares of the company's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares of the company's stock, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Stryker Trading Up 1.1%

NYSE SYK opened at $370.59 on Friday. The stock has a 50-day simple moving average of $382.81 and a 200 day simple moving average of $378.92. The company has a market capitalization of $141.68 billion, a PE ratio of 49.08, a P/E/G ratio of 2.64 and a beta of 0.94. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm's revenue was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Research analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's dividend payout ratio is currently 44.50%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on SYK shares. Rothschild Redb raised Stryker to a "hold" rating in a research note on Thursday, September 18th. Wall Street Zen lowered Stryker from a "buy" rating to a "hold" rating in a research note on Friday, September 26th. Needham & Company LLC boosted their price objective on Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. BTIG Research reissued a "buy" rating on shares of Stryker in a research note on Monday, July 14th. Finally, Wells Fargo & Company boosted their target price on Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a research report on Friday, August 1st. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $430.33.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.